231 related articles for article (PubMed ID: 24097127)
1. Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.
Tirmenstein M; Dorr TE; Janovitz EB; Hagan D; Abell LM; Onorato JM; Whaley JM; Graziano MJ; Reilly TP
Int J Toxicol; 2013; 32(5):336-50. PubMed ID: 24097127
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin.
Bogdanffy MS; Stachlewitz RF; van Tongeren S; Knight B; Sharp DE; Ku W; Hart SE; Blanchard K
Int J Toxicol; 2014; 33(6):436-49. PubMed ID: 25260362
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
Obermeier M; Yao M; Khanna A; Koplowitz B; Zhu M; Li W; Komoroski B; Kasichayanula S; Discenza L; Washburn W; Meng W; Ellsworth BA; Whaley JM; Humphreys WG
Drug Metab Dispos; 2010 Mar; 38(3):405-14. PubMed ID: 19996149
[TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
Komoroski B; Vachharajani N; Boulton D; Kornhauser D; Geraldes M; Li L; Pfister M
Clin Pharmacol Ther; 2009 May; 85(5):520-6. PubMed ID: 19129748
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Kasichayanula S; Liu X; Lacreta F; Griffen SC; Boulton DW
Clin Pharmacokinet; 2014 Jan; 53(1):17-27. PubMed ID: 24105299
[TBL] [Abstract][Full Text] [Related]
8. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
Kasichayanula S; Liu X; Griffen SC; Lacreta FP; Boulton DW
Diabetes Obes Metab; 2013 Mar; 15(3):280-3. PubMed ID: 23061428
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
Han S; Hagan DL; Taylor JR; Xin L; Meng W; Biller SA; Wetterau JR; Washburn WN; Whaley JM
Diabetes; 2008 Jun; 57(6):1723-9. PubMed ID: 18356408
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):423-36. PubMed ID: 22139434
[TBL] [Abstract][Full Text] [Related]
11. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Komoroski B; Vachharajani N; Feng Y; Li L; Kornhauser D; Pfister M
Clin Pharmacol Ther; 2009 May; 85(5):513-9. PubMed ID: 19129749
[TBL] [Abstract][Full Text] [Related]
13. Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2.
Gould JC; Kasichayanula S; Shepperly DC; Boulton DW
Regul Toxicol Pharmacol; 2013 Oct; 67(1):89-97. PubMed ID: 23851069
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Calado J
IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.
Lee TM; Chang NC; Lin SZ
Free Radic Biol Med; 2017 Mar; 104():298-310. PubMed ID: 28132924
[TBL] [Abstract][Full Text] [Related]
16. Urinary tract infections in patients with diabetes treated with dapagliflozin.
Johnsson KM; Ptaszynska A; Schmitz B; Sugg J; Parikh SJ; List JF
J Diabetes Complications; 2013; 27(5):473-8. PubMed ID: 23849632
[TBL] [Abstract][Full Text] [Related]
17. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM; White JR
Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
[TBL] [Abstract][Full Text] [Related]
19. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
20. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]